Department of Orthopaedics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, PR China.
Department of Orthopaedics, The No. 1 People's Hospital of Yancheng, Yancheng, Jiangsu, PR China.
J Cell Mol Med. 2020 Nov;24(21):12633-12641. doi: 10.1111/jcmm.15828. Epub 2020 Sep 18.
Long non-coding RNAs have been demonstrated to be important regulators of various cancers, though the precise mechanisms remain unclear. Although lincFOXF1 has been reported to act as a tumour suppressor, its function and underlying mechanisms in osteosarcoma have not yet been explored. We employed quantitative real-time polymerase chain reaction (qRT-PCR) to evaluate the expression of lincFOXF1 and GAPDH in osteosarcoma tissues and cell lines, and colony-formation, CCK8, wound-healing, and transwell assays were conducted to analyse the proliferation, migration, and invasion capacity of osteosarcoma cells. Subcellular localization analysis by fractionation and RNA immunoprecipitation assays were performed to elucidate the mechanism responsible for lincFOXF1-mediated phenotypes of osteosarcoma cells. The results revealed that lincFOXF1 expression is significantly decreased and strongly related to Enneking stage as well as metastasis in osteosarcoma patients. Further experiments showed that lincFOXF1 inhibits the migration, invasion and metastasis of cells in vitro and vivo. Mechanistic investigation demonstrated that lincFOXF1 physically binds to EZH2, a polycomb repressive complex 2 (PRC2) component, and a search for downstream targets suggested that G-protein-coupled receptor kinase-interacting protein 1 (GIT1) is involved in the lincFOXF1-mediated repression of osteosarcoma cells migration and invasion. Moreover, GIT1 expression is inversely correlated with lincFOXF1 in osteosarcoma. The present findings indicate that lincFOXF1 is involved in the progression of osteosarcoma through binding with EZH2, further regulating GIT1 expression. Our results suggest that lincFOXF1 may serve as a biomarker and therapeutic target for osteosarcoma patients.
长链非编码 RNA 已被证明是多种癌症的重要调控因子,但其确切机制尚不清楚。虽然 lincFOXF1 已被报道为肿瘤抑制因子,但它在骨肉瘤中的功能和潜在机制尚未被探索。我们采用实时定量聚合酶链反应(qRT-PCR)评估 lincFOXF1 和 GAPDH 在骨肉瘤组织和细胞系中的表达,并进行集落形成、CCK8、划痕愈合和 Transwell 测定以分析骨肉瘤细胞的增殖、迁移和侵袭能力。通过分馏和 RNA 免疫沉淀测定进行亚细胞定位分析,以阐明 lincFOXF1 介导骨肉瘤细胞表型的机制。结果表明,lincFOXF1 的表达明显降低,与骨肉瘤患者的 Enneking 分期和转移密切相关。进一步的实验表明,lincFOXF1 抑制细胞在体外和体内的迁移、侵袭和转移。机制研究表明,lincFOXF1 与 EZH2(多梳抑制复合物 2(PRC2)的一个组成部分)物理结合,并对下游靶标进行搜索表明 G 蛋白偶联受体激酶相互作用蛋白 1(GIT1)参与了 lincFOXF1 介导的骨肉瘤细胞迁移和侵袭的抑制。此外,在骨肉瘤中 GIT1 的表达与 lincFOXF1 呈负相关。这些发现表明,lincFOXF1 通过与 EZH2 结合参与骨肉瘤的进展,进一步调节 GIT1 的表达。我们的研究结果表明,lincFOXF1 可能作为骨肉瘤患者的生物标志物和治疗靶标。